Icon

DANZITEN (NDA219293)- (71MG,95MG)

NILOTINIB TARTRATE AZURITY PHARMACEUTICALS INC
71MG,95MG
No Yes
Expired Expired
None None
None No
DANZITEN is a kinase inhibitor indicated for the treatment of: 1)Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 2) Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.
0 0 0
Total Other Developers None
Drugs with Suitability No
71MG ** ** - - -
95MG ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.